Inspire Medical announced upcoming presentations and events highlighting its neurostimulator therapy for obstructive sleep apnea at the International Surgical Sleep Society and American Academy of Otolaryngology meetings.
By identifying who’s at risk of failing CPAP, such data could prompt clinicians to intervene for patients likely to face adherence challenges.
The Air11 device-to-cloud data transmission delay issue that ResMed CPAP users had been experiencing has been resolved.
ResMed is addressing myAir and AirView sync delays, assuring that patient data is securely stored on their devices, with full system restoration expected in the coming weeks.
Vivos Therapeutics reported a decline in product revenue and enrollments in the second quarter, a dip it attributed to governmental investigations into third parties offering non-FDA-approved sleep apnea treatments.
'The American health care system has joined with commercial partners to define sleep apnea in a way that allows both parties to generate revenue from a multitude of pricey diagnostic studies, equipment sales, and questionable treatments.'
The investment will help prepare the device for volume manufacturing, develop the clinician and patient-led online platform, and achieve first sales.
Treatment for OSA typically starts downstream with the throat, instead of upstream in the nose, the first site of breathing difficulty.
The therapy was found to provide a "substantial reduction” in symptoms for adult patients with RLS refractory to medications, according to two newly published studies.
Nyxoah announced operating results for the second quarter and first half of 2023, emphasizing advances in its investigational device exemption trial designed to support the marketing authorization of the Genio neurostimulator system for the treatment of OSA.
Sleep Review‘s nasal dilators guide compares the devices on parameters such as availability, price, sizes, materials, usage, and supporting studies, as well as advises on how sleep professionals can request samples.
An inexpensive machine commonly used for pain relief has shown to improve breathing in patients with obstructive sleep apnea, a clinical trial has found.
New Alzheimer’s research suggests that enhanced light sensitivity may contribute to “sundowning”—the worsening of symptoms late in the day—and spur sleep disruptions thought to contribute to the disease’s progression.
Investigators found that positive sound exposure, used in conjunction with imagery rehearsal therapy, produced promising results for individuals with nightmare disorders.
The FDA has granted another clearance to the React Health Luna G3 Bilevel S/T 30Vt, which expands the utilization of the device beyond the sleep-disordered breathing space.